Literature DB >> 15247183

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

J Thulesen1, B Hartmann, K J Hare, H Kissow, C Ørskov, J J Holst, S S Poulsen.   

Abstract

BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine. AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.
METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.
RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.
CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247183      PMCID: PMC1774162          DOI: 10.1136/gut.2003.035212

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  32 in total

1.  Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans.

Authors:  Q Xiao; R P Boushey; D J Drucker; P L Brubaker
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

Review 2.  Nutrient regulation of intestinal growth and adaptation: role of glucagon-like peptide 2 and the enteroendocrine cell.

Authors:  D C Rubin
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

3.  Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2.

Authors:  P L Brubaker; A Izzo; M Hill; D J Drucker
Journal:  Am J Physiol       Date:  1997-06

4.  Intestinal growth-promoting properties of glucagon-like peptide-2 in mice.

Authors:  C H Tsai; M Hill; S L Asa; P L Brubaker; D J Drucker
Journal:  Am J Physiol       Date:  1997-07

5.  Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2.

Authors:  P L Brubaker; A Crivici; A Izzo; P Ehrlich; C H Tsai; D J Drucker
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

6.  Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.

Authors:  M Wøjdemann; A Wettergren; B Hartmann; L Hilsted; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

7.  The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.

Authors:  M Tang-Christensen; P J Larsen; J Thulesen; J Rømer; N Vrang
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

8.  Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2.

Authors:  J Thulesen; B Hartmann; C Orskov; P B Jeppesen; J J Holst; S S Poulsen
Journal:  Peptides       Date:  2000-10       Impact factor: 3.750

9.  Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.

Authors:  D G Munroe; A K Gupta; F Kooshesh; T B Vyas; G Rizkalla; H Wang; L Demchyshyn; Z J Yang; R K Kamboj; H Chen; K McCallum; M Sumner-Smith; D J Drucker; A Crivici
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport.

Authors:  C I Cheeseman; R Tsang
Journal:  Am J Physiol       Date:  1996-09
View more
  21 in total

Review 1.  The use of hormonal growth factors in the treatment of patients with short-bowel syndrome.

Authors:  Palle B Jeppesen
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Effects of growth factors and receptor blockade on gastrointestinal cancer.

Authors:  R J Playford; H Wassan; S Ghosh
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 3.  Cellular and molecular mechanisms of the epithelial repair in IBD.

Authors:  Ryuichi Okamoto; Mamoru Watanabe
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 4.  Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features.

Authors:  Valérie Haydont; Marie-Catherine Vozenin-Brotons
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

Review 5.  Management and Complications of Short Bowel Syndrome: an Updated Review.

Authors:  Robert E Carroll; Enrico Benedetti; Joseph P Schowalter; Alan L Buchman
Journal:  Curr Gastroenterol Rep       Date:  2016-07

Review 6.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Authors:  G-R Martin; P-L Beck; D-L Sigalet
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

Review 7.  Epithelial restitution and wound healing in inflammatory bowel disease.

Authors:  Andreas Sturm; Axel U Dignass
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.

Authors:  Jacqueline A Koehler; Will Harper; Maja Barnard; Bernardo Yusta; Daniel J Drucker
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Authors:  P B Jeppesen; P Lund; I B Gottschalck; H B Nielsen; J J Holst; J Mortensen; S S Poulsen; B Quistorff; P B Mortensen
Journal:  Gastroenterol Res Pract       Date:  2009-08-20       Impact factor: 2.260

10.  Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability.

Authors:  P D Cani; S Possemiers; T Van de Wiele; Y Guiot; A Everard; O Rottier; L Geurts; D Naslain; A Neyrinck; D M Lambert; G G Muccioli; N M Delzenne
Journal:  Gut       Date:  2009-02-24       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.